North America Drug Delivery Market Size, Share & Industry Analysis, By Type (Oral {Tablet [Oral Dispersible Tablets, Modified Release Tablets, Coated Tablets & Others], Capsules, Liquid or Syrup, & Others} & Injectable {Conventional Injectables, Pre-filled Syringes, Auto-injectors, Pen-injectors, Wearable Injectors, & Others}), By Device Type (Conventional & Advanced), By Application Area (Central Nervous System, Digestive System (Metabolism), Endocrine System, Immune System, & Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Others), & Regional Forecast, 2025-2032

The North America drug delivery market size was valued at USD 702.04 billion in 2024. The market is projected to grow from USD 743.20 billion in 2025 to USD 1,175.47 billion by 2032, exhibiting a CAGR of 6.8% during the forecast period.

Drug delivery is the process of giving medications to patients through several routes of administration. Moreover, the drug delivery technology also deals with dosage forms such as tablets, liquids, syrups, and capsules, amongst others. The primary focus of drug delivery is to make sure that the medicine reaches the body in the right amount. The growth of the North America drug delivery market is attributed to the rising prevalence of chronic diseases, investments by pharmaceutical companies, and strong research & development activities.

Moreover, a surge in demand for targeted biologics and cell therapies and the increasing introduction and adoption of connected drug delivery systems offer a significant opportunity for market growth. These smart systems, which integrate wireless communication technologies such as Bluetooth, Near Field Communication (NFC), and mobile applications, enable real-time monitoring of patient adherence, dosage accuracy, and therapeutic efficiency.

Some of the major players in the market are BD, Novartis AG, Baxter, West Pharmaceutical Services Inc., and Novo Nordisk. These players focus on strong research & development activities, technological advancements, extensive investments, and strategic agreements to hold a considerable market share along with an extended customer base.

MARKET DYNAMICS

Market Drivers

Prevalence of Chronic Conditions Coupled with Rising Geriatric Population Boost Market Growth

The growing geriatric population is one of the prominent drivers for North America’s drug delivery market. This population demands ergonomic drug delivery systems, along with efficient access and usability for drug delivery solutions. In addition, the prevalence of chronic conditions leads to long-term therapy needs and reliable dosing. Further, manufacturers are emphasizing developing novel products that will cater to the demand and specific requirements for this population, consequently leading to North America drug delivery market growth.

• For instance, in August 2023, Kakao Healthcare entered into a strategic partnership with Novo Nordisk for further development of its AI-based diabetes management service. This smart platform will help both patients and caregivers with better diabetes management.

Furthermore, at-home care programs coupled with the growing demand for wearable injectors due to enhanced convenience are projected to have a positive impact on the market growth. The companies are making efforts to expand their production capacities with an aim to bridge the gap between demand and supply.  

• In April 2023, LTS LOHMANN Therapie-Systeme AG announced the acquisition of the wearable injection business from Eitan Medical. By this acquisition, the company will gain the ability to offer large volume and large molecule injectables.

Market Restraints

High Cost of Compliance with Safety Regulations to Deter Market Growth

The high cost of compliance, along with stringent quality and safety regulations will hamper market growth. The government strictly validates the quality and safety of every newly developed drug-filled product in order to improve patient safety and the effectiveness of medications. The process also includes stability testing, packaging validation, human assessment, and detailed labeling reviews. Changes in these processes take an extended time and cost, leading to delayed product introduction.

Smaller companies often struggle to manage these costs and delays, which can discourage innovation and slow the introduction of more convenient formats. For oral products, dissolution testing, coating integrity checks, and food interaction studies add similar burdens. While these measures protect patient safety, they also create a heavy, ongoing workload for manufacturers and regulatory teams.

• For instance, according to data published by Cancer Research UK, it takes nearly 10 to 15 years to complete all phases of clinical trials for a new drug candidate. This span varies for each drug candidate.

Market Opportunities

Rising Adoption of Connected Drug Delivery Systems Offer Expansion Opportunities

An increasing adoption of connected drug delivery devices is anticipated to offer a favorable market opportunity. At present, connected drug delivery devices include a range of products from autoinjectors, wearable injectors, inhalers, and smart pill bottles. These devices are equipped with advanced tracking technologies, enabling patients to track medication usage, dosage reminders, and patient data sharing with healthcare providers. Drug delivery systems with such advanced functionalities are further projected to offer a favorable environment for market growth by 2032.

• For instance, in March 2023, Diabeloop announced its plan to collaborate with Novo Nordisk. The agreement was commenced to develop a connected and automated insulin delivery device with the help of self-learning algorithms.

Moreover, the connected systems also offer substantial value to healthcare providers and payers by reducing hospitalization rates and enabling remote patient monitoring, thereby lowering overall treatment costs.

Market Challenges

High Device Recall Rates Challenge Market Growth

The drug delivery market in North America is estimated to witness substantial challenges of high device recall rates. These recalls lead to litigation, thereby heading to reputational and financial setbacks. As this market is heavily regulated and litigation-prone, even minor design defects or adverse event reports can cause nationwide product recalls.

• For instance, in October 2024, Medtronic announced a recall of its insulin pump due to shortened battery life. Moreover, the issue of irregular delivery was also noticed in its operations.

In addition, devices such as autoinjectors, infusion pumps, and wearable injectors, especially when combined with high-potency biologics, carry increased risk due to mechanical failures, dose inaccuracies, or material degradation. A single failure can not only compromise patient safety but also raise concerns about systemic quality control, prompting immediate regulatory investigations and class-action lawsuits.

NORTH AMERICA DRUG DELIVERY MARKET TRENDS

Growing Emphasis on Personalized Therapies Drive Innovations in Oral and Injectable Delivery

In North America, pharmaceuticals are witnessing growing demand for patient-centric and personalized therapies in oral as well as injectable dosage forms. Due to this demand, pharmaceutical companies are focusing on leveraging pharmacogenomics, real-time health monitoring, and AI-driven analytics with an aim to refine dosage forms as per individual patient needs. In oral delivery segment, there is a rising preference for 3D-printed pills, microbiome-responsive capsules, and multi-layer modified-release tablets.

• For instance, in February 2021, Triastek, Inc. received FDA approval for its first 3D printed product, T19, which is formulated to treat rheumatoid arthritis.

Furthermore, the growing adoption of biologics and precision therapies is driving demand for smart autoinjectors, wearable injectors, and connected prefilled syringes with integrated sensors. These devices monitor administration, detect potential errors, and securely share data with healthcare providers.

Download Free sample to learn more about this report.

SEGMENTATION ANALYSIS

By Type

Significant Adoption of Biologics, Targeted Therapies, and Specialty Drugs Boost Injectable Growth

Based on type, the market is segmented into oral and injectable. The injectable segment dominated the North America drug delivery market share in 2024. The segment’s growth is attributed to substantial adoption of biologics, targeted therapies, and specialty drugs. In addition, the availability of technologically advanced drug delivery systems such as pen injectors, autoinjectors, and others is responsible for the elevated adoption of injectable types in the region.

• For instance, in the financial year 2023, Amneal Pharmaceuticals LLC recorded the market launch of around 39 new retail and injectable products in the U.S.

On the other hand, oral types also held a considerable market share in 2024 driven by ease of administration, non-invasiveness, and high patient compliance. Moreover, it remains the first-line delivery route for a wide range of therapeutic classes, especially for chronic diseases such as hypertension, diabetes, and gastrointestinal disorders.

By Device Type

Adequate Product Availability of Conventional Devices to Boost Segment Growth

Based on device type, the market is bifurcated into conventional and advanced. The conventional devices held the largest market share in 2025. The adoption of conventional devices is generally higher due to their low cost, availability, simplicity, and extensive manufacturing capabilities. Moreover, the distribution and supply of conventional devices is also comparatively higher as compared to advanced devices.

• For instance, in April 2025, Novartis announced its plan to expand its manufacturing capabilities in the U.S. The company is planning to invest USD 23.0 billion in the upcoming five years for this expansion.

The advanced devices segment is projected to exhibit the fastest CAGR during the forecast period. The growth of this segment is prominently driven by a higher number of candidates in clinical trials, the rising introduction of biologics, focus on precision medicine, and patient preference for at-home therapeutic options.

By Application Area

Substantial Prevalence of Immune Disorders Boost Segment Growth

Based on application area, the market is fragmented into the central nervous system (CNS), digestive system (metabolism), endocrine system, immune system, and others. The immune system segment dominated the market in 2024 with prevalence of autoimmune conditions and chronic inflammatory conditions, amongst others. Strong research and development activities in the immune system sector are also estimated to have a positive impact on the segment’s growth.

• For instance, in October 2023, Sanofi and Teva announced a strategic collaboration for the development of inflammatory bowel disease therapeutics.

The endocrine system segment is estimated to register the fastest CAGR during the forecast period with increasing incidence of diabetes and thyroid-related disorders.

By Distribution Channel

A Growing Number of Product Launches Boosted Steam Sterilization Segment Growth

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominated the market in 2024 and is expected to expand at a considerable CAGR during the forecast period. Hospital pharmacies are the primary channel of oral and injectable supplies. Moreover, these facilities handle a wide range of complex therapies, including injectables, biologics, and specialty drugs that require close monitoring and professional administration.

The retail pharmacies segment is estimated to register the fastest CAGR during the forecast period. Certain factors, such as increasing need for drug supplying facilities, rising investments by retail chains, and supportive government policies also boost segment growth.

• For instance, in June 2025, CVS Health announced its plan to invest USD 20 billion in the upcoming 10 years to develop and integrate hi-tech solutions in the healthcare system.

NORTH AMERICA DRUG DELIVERY MARKET REGIONAL OUTLOOK

By geography, the market is categorized into the U.S. and Canada.

U.S.

The U.S. dominated the global market in 2024, with the market standing at USD 656.60 billion. The growth of the U.S. drug delivery market is attributed to robust healthcare infrastructure, focus on innovation, and substantial prevalence of chronic conditions. Furthermore, the focus of market players is on strategic collaborations and investments to accelerate market growth.

• For instance, in August 2025, AbbVie announced its plan to invest USD 195 million for the expansion of API (Active Pharmaceutical Ingredient) in the U.S.

Canada

The Canada drug delivery market is estimated to register the fastest CAGR during the forecast period. Extensive clinical trials, technological advancements, and supportive policies also boost market growth. In addition, growing awareness about precision medicine and targeted therapies is also projected to accelerate market growth by 2032.

• For instance, in January 2025, AstraZeneca announced its plan to invest USD 570 million in order to boost its clinical studies and clinical delivery. The company has a plan to build a state of the art facility in Canada.

COMPETITIVE LANDSCAPE

Key Industry Players

Market Players Emphasize Expansion to Boost Their Market Share

The North America drug delivery market is fragmented as a higher number of companies account for a major market share. Pfizer Inc., BD, and Merck & Co., among a few others, are prominently players operating in the market. Growing emphasis on providing novel drug delivery solutions for chronic conditions and technological advancements are responsible for market growth. Additionally, BD, Catelent Inc., Novo Nordisk, and others are also actively engaged in order to expand their share of the North America drug delivery market. The industry is witnessing a rising trend of acquisitions and mergers, with key players seeking to consolidate their position and boost market share.

LIST OF KEY NORTH AMERICA DRUG DELIVERY COMPANIES PROFILED

• Gerresheimer AG (Germany)
• BD (U.S.)
• Catalent, Inc. (U.S.)
• Baxter (U.S.)
• West Pharmaceutical Services (U.S.)
• Ypsomed (Switzerland)
• Medtronic (Ireland)
• Nemera (France)

KEY INDUSTRY DEVELOPMENTS

• December 2024: Novo Holdings A/S completed the acquisition of Catelent for a value of USD 16.5 billion.
• October 2024: Nemera introduced a new reusable auto-injector at CPhI Milan. This latest offering is part of Nemera's broader portfolio of injection devices, which accounts for 44% of its sales and serves a wide range of therapeutic areas, particularly chronic diseases that involve self-drug administration, such as diabetes, obesity, immunology, and oncology.
• April 2024: Baxter received U.S. FDA clearance for its Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, enhancing connected and intelligent infusion therapy with a unified platform for large volume and syringe infusion pumps.
• October 2021: BD partnered with Aptar Pharma and launched BD SCF PremiumCoat Plunger Stopperade to support biologics injection with a pre-filled syringe.
• March 2021: Jabil Healthcare entered into a strategic collaboration agreement with E3D, a member of the Elcam Medical Group. This partnership grants Jabil access to E3D's reusable mechanical auto-injector technology and provides Jabil with exclusive rights to develop a high-volume reusable auto-injector platform, including connected variants.

REPORT COVERAGE

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation